Thalassemia – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Thalassemia is an inherited blood disorder that reduces the production of functional hemoglobin (the protein in red blood cells that carries oxygen). This causes a shortage of red blood cells and low levels of oxygen in the bloodstream, leading to a variety of health problems. Etiology- Mutations in the HBB gene lead to reduced levels of beta-globin and cause beta-thalassemia. Loss (deletion) of some or all of the HBA1 and/or HBA2 genes results in a shortage of alpha-globin, leading to alpha thalassemia. The competitive landscape of Thalassemia includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary. KOLs insights of Thalassemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and ...